Craft

BioNTech

Stock Price

€114.6

2023-08-30

Market Capitalization

€28 B

2023-08-30

Revenue

€17.3 B

FY, 2022

BioNTech Summary

Company Summary

Overview
BioNTech is a biopharmaceutical company developing therapies against cancer and infectious diseases. It provides peptide manufacturing services, GMP (good manufacturing practice) manufacturing services for mRNA and cell and gene therapies, and research services. The company also develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products through selected partners. BioNTech covers a range of platforms, including mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
Type
Public
Status
Active
Founded
2008
HQ
Mainz, DE | view all locations
Website
https://biontech.de/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Sean Marett

    Sean Marett, Chief Business and Chief Commercial Officer

  • Ugur Sahin

    Ugur Sahin, Chief Executive Officer

  • Ryan Richardson

    Ryan Richardson, Chief Strategy Officer

  • Ozlem Tureci

    Ozlem Tureci, Chief Medical Officer

Operating MetricsView all

Scientific Collaborations

7

Oct, 2019

Phase II Trials Products

1

Oct, 2019

Pre-Clinical Phase Products

11

Oct, 2019

LocationsView all

8 locations detected

  • Mainz, RP HQ

    Germany

    An der Goldgrube 12

  • Cambridge, MA

    United States

    40 Erie St #110

  • San Diego, CA

    United States

    11535 Sorrento Valley Rd #400

  • Halle (Saale), SA

    Germany

    Weinbergweg 23

  • Idar-Oberstein, RP

    Germany

    Vollmersbachstraße 66

  • Marburg, HE

    Germany

    Emil-von-Behring-Straße 76

and 2 others

BioNTech Financials

Summary Financials

Revenue (Q2, 2023)
€167.7M
Gross profit (Q2, 2023)
€15.8M
Net income (Q2, 2023)
(€190.4M)
Cash (Q2, 2023)
€14.2B
EBIT (Q2, 2023)
(€504.7M)
Enterprise value
$14.1B

Blogs

Footer menu